David Domzalski
President & CEO
Claimed by owner VYNE Therapeutics
Former names: Foamix Pharmaceuticals, Menlo Therapeutics
Therapies for the Treatment of Immuno-inflammatory Conditions
Acquired by Menlo Therapeutics on Nov, 2019
VYNE Therapeutics
www.globenewswire.com
•
Feb 22, 2023
VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
finance.yahoo.com
•
Jan 9, 2023
VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201
finance.yahoo.com
•
Dec 7, 2022
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
finance.yahoo.com
•
Nov 17, 2022
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
seekingalpha.com
•
Apr 7, 2022
VYNE Therapeutics reports positive data from phase 1 trial of atopic dermatitis therapy
finance.yahoo.com
•
Feb 15, 2022
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201
www.prnewswire.com
•
Oct 1, 2020
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st
www.globenewswire.com
•
Sep 14, 2020
VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors
www.globenewswire.com
•
Sep 8, 2020
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics
www.dermatologytimes.com
•
Sep 2, 2020
Menlo Therapeutics changes name to VYNE Therapeutics
www.globenewswire.com
•
Feb 18, 2020
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
www.dermatologytimes.com
•
Feb 14, 2020
Foamix and Menlo announce approval of merger
www.globenewswire.com
•
Jan 17, 2020
Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics
en.globes.co.il
•
Nov 11, 2019
Israeli dermatology co Foamix merging with US co Menlo
seekingalpha.com
•
Aug 12, 2019
With 2 NDAs Already Submitted To The FDA, Foamix Sets Itself Up For A Monumental Period (NASDAQ:FOMX)
www.prnewswire.com
•
Aug 5, 2019
Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea
en.globes.co.il
•
Jul 30, 2019
Dermatology drug development co Foamix raises $64m
www.globenewswire.com
•
Jun 4, 2019
Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology
www.globenewswire.com
•
Apr 2, 2019
Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam
www.globenewswire.com
•
Mar 7, 2019
Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne
www.globenewswire.com
•
Feb 27, 2019
Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to 1 Year
www.globenewswire.com
•
Jan 23, 2019
Foamix Announces Appointment of Sharon Barbari to Board of Directors
www.globenewswire.com
•
Dec 21, 2018
Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
www.globenewswire.com
•
Nov 27, 2018
Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
www.globenewswire.com
•
Nov 19, 2018
Foamix Announces Appointment of Anthony Bruno to Board of Directors
www.globenewswire.com
•
Nov 7, 2018
Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
en.globes.co.il
•
Sep 13, 2018
Foamix plans $70m offering after acne trial success
www.globenewswire.com
•
Sep 11, 2018
Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
www.globenewswire.com
•
Jan 4, 2018
Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year
www.globenewswire.com
•
Jan 3, 2018
Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals
www.prnewswire.com
•
Jun 29, 2017
Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer
medcitynews.com
•
Mar 27, 2017
Allergan and Paratek nail pivotal acne trial, while Foamix makes a late-stage stumble
www.globes.co.il
•
Aug 2, 2015
Foamix product approval worth $10m annually
www.globes.co.il
•
May 5, 2015
Dermatology drug co Foamix takes on US market
www.globes.co.il
•
Apr 15, 2015
Foamix raises $60m in Nasdaq secondary offering
www.globes.co.il
•
Apr 2, 2015
Foamix Pharmaceuticals Nasdaq IPO slashed to $40m
About
VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.
VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, a topical minocycline; and ZILXI (minocycline) topical foam, 1.5%, a minocycline product for the treatment of rosacea.
The company was formed from the merger of Foamix, an Israeli clinical-stage specialty pharmaceutical company, and Menlo Therapeutics, a US-based dermatology company.
VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, a topical minocycline; and ZILXI (minocycline) topical foam, 1.5%, a minocycline product for the treatment of rosacea.
The company was formed from the merger of Foamix, an Israeli clinical-stage specialty pharmaceutical company, and Menlo Therapeutics, a US-based dermatology company.
Primary Sector
Life Sciences & HealthTech
Products
Amzeeq, ZILXI
Geographic markets
Israel, United States
News
(36)
www.globenewswire.com
•
Feb 22, 2023
VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
finance.yahoo.com
•
Jan 9, 2023
VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201
finance.yahoo.com
•
Dec 7, 2022
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
finance.yahoo.com
•
Nov 17, 2022
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
seekingalpha.com
•
Apr 7, 2022
VYNE Therapeutics reports positive data from phase 1 trial of atopic dermatitis therapy
finance.yahoo.com
•
Feb 15, 2022
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201
www.prnewswire.com
•
Oct 1, 2020
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st
www.globenewswire.com
•
Sep 14, 2020
VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors
www.globenewswire.com
•
Sep 8, 2020
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics
www.dermatologytimes.com
•
Sep 2, 2020
Menlo Therapeutics changes name to VYNE Therapeutics
www.globenewswire.com
•
Feb 18, 2020
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
www.dermatologytimes.com
•
Feb 14, 2020
Foamix and Menlo announce approval of merger
www.globenewswire.com
•
Jan 17, 2020
Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics
en.globes.co.il
•
Nov 11, 2019
Israeli dermatology co Foamix merging with US co Menlo
seekingalpha.com
•
Aug 12, 2019
With 2 NDAs Already Submitted To The FDA, Foamix Sets Itself Up For A Monumental Period (NASDAQ:FOMX)
www.prnewswire.com
•
Aug 5, 2019
Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea
en.globes.co.il
•
Jul 30, 2019
Dermatology drug development co Foamix raises $64m
www.globenewswire.com
•
Jun 4, 2019
Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology
www.globenewswire.com
•
Apr 2, 2019
Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam
www.globenewswire.com
•
Mar 7, 2019
Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne
www.globenewswire.com
•
Feb 27, 2019
Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to 1 Year
www.globenewswire.com
•
Jan 23, 2019
Foamix Announces Appointment of Sharon Barbari to Board of Directors
www.globenewswire.com
•
Dec 21, 2018
Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
www.globenewswire.com
•
Nov 27, 2018
Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
www.globenewswire.com
•
Nov 19, 2018
Foamix Announces Appointment of Anthony Bruno to Board of Directors
www.globenewswire.com
•
Nov 7, 2018
Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
en.globes.co.il
•
Sep 13, 2018
Foamix plans $70m offering after acne trial success
www.globenewswire.com
•
Sep 11, 2018
Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
www.globenewswire.com
•
Jan 4, 2018
Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year
www.globenewswire.com
•
Jan 3, 2018
Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals
www.prnewswire.com
•
Jun 29, 2017
Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer
medcitynews.com
•
Mar 27, 2017
Allergan and Paratek nail pivotal acne trial, while Foamix makes a late-stage stumble
www.globes.co.il
•
Aug 2, 2015
Foamix product approval worth $10m annually
www.globes.co.il
•
May 5, 2015
Dermatology drug co Foamix takes on US market
www.globes.co.il
•
Apr 15, 2015
Foamix raises $60m in Nasdaq secondary offering
www.globes.co.il
•
Apr 2, 2015
Foamix Pharmaceuticals Nasdaq IPO slashed to $40m
The Team
(4)
DD
ME
Meir Eini
Founder - Foamix Pharamecutials
TZ
Tyler Zeronda
CFO
IS
Iain Stuart
Chief Scientific Officer, Head of R&D
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
$40M
Sep 2014
Stock Exchange
NASDAQ
Valuation
$128M
$40M
M&A
Undisclosed
Nov 2019
Type
Merger
Merged to
Menlo Therapeutics
Undisclosed
Private Equity Funding
Post-IPO Equity Funding
$60M
Apr 2015
$60M
Post-IPO Equity Funding
$16M
Apr 2018
1 Investors
$16M
Post-IPO Equity Funding
$64M
Jul 2019
2 Investors
$64M
Media gallery
(0)Locations
Israel
Golda Me'ir Street 7, Ness Ziona, Israel
Offices Abroad
520 U.S. 22, Bridgewater Township, NJ, USA
Locations
Israel
Golda Me'ir Street 7, Ness Ziona, Israel
Offices Abroad
520 U.S. 22, Bridgewater Township, NJ, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,